Affiliation:
1. UCLA Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California
2. Southern California Kaiser Permanente Health Care Plan, Los Angeles, California
3. GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania
Abstract
BACKGROUND. Prelicensure studies of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus vaccine suggested that there were higher rates of fever after its administration than when its component antigens were given separately.
METHODS. We conducted an open, controlled, cohort study to evaluate selected potential adverse events after receipt of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine in the Southern California Kaiser Permanente Health Care Plan. From April 2003 through June 2005, we identified 61004 infants who received ≥1 dose of vaccine (120000 total doses). This group was compared with a previous cohort of 58251 age-, gender-, and medical center–matched infants (116637 doses) who received diphtheria, tetanus, acellular pertussis vaccine and separate doses of hepatitis B and inactivated poliovirus vaccines from January 2002 through March 2003. We compared the incidence of seizures, medically attended events that were associated with fever, and other selected adverse outcomes.
RESULTS. We identified 16 infants (8 with fever) who had a seizure in the diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus cohort and 15 infants (6 with fever) among control subjects in the 8-day period after receipt of any dose of vaccine. The incidence of all seizures or seizures associated with fever was not significantly different between cohorts. The incidence of medically attended events that were associated with fever in the 4-day period after any dose of vaccine was also similar in both cohorts. As well, no significant differences between the diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and control cohorts, were noted in the incidence of allergic reactions within 48 hours of any dose of vaccine, outpatient visits within 21 days, hospitalizations within 21 days, or death within 1 year.
CONCLUSIONS. We did not observe a statistically significant increase in any of several clinically important safety events after diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccination compared with a historical cohort who received separate component vaccines.
Publisher
American Academy of Pediatrics (AAP)
Subject
Pediatrics, Perinatology, and Child Health
Reference24 articles.
1. World Health Organization. Conclusion and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 27–28 November, 2007. Wkly Epidemiol Rec. 2008;83(3):25–36
2. Meyerhoff A, Jacobs R, Greenberg D, Yagoda B, Castles C. Clinician satisfaction with vaccination visits and the role of multiple injections, results from the COVISE Study (Combination Vaccines Impact on Satisfaction and Epidemiology). Clin Pediatr (Phila). 2004;43(1):87–93
3. Happe L, Lunascek O, Marshall G, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13(9):506–512
4. Marshall G, Happe L, Lunascek O, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496–500
5. Combination vaccines for childhood immunization. MMWR Recomm Rep. 1999;48(RR-5):1–14